



THE UNIVERSITY OF TEXAS
MDAnderson
Cancer Center
Making Cancer History®

Advances in precision oncology
with targeted treatment
and immunotherapy

제 24회 연세 송당 암 연구센터 국제 암 심포지엄

24th International Symposium of
Yonsei Song-dang Institute for Cancer Research

일시 2018년 11월 2일(금) / 09:00 ~ 16:00

장소 연세대학교 의과대학 에비슨의생명연구소 유일한홀(1층)

09:00-09:05 **Opening address** **Hyun Cheol Chung, MD, PhD** Director, Yonsei Song-dang Institute for Cancer Research, Korea

09:05-09:10 **Welcome address** **Yang Soo Jang, MD, PhD** Dean, Yonsei University College of Medicine, Korea

Session I Emerging landscape for precision oncology with clinically actionable data

09:10-09:30 Drugging undruggable targets for cancer precision medicine by a chemical genomic approach **Wan Kyu Kim, PhD** Ewha Womans University, Korea

09:30-09:50 Dynamics of multi-omic aberrations in liver cancer **Hyun Goo Woo, MD, PhD** Ajou University, Korea

Session II Preparing successful early phase trials from clinical sequencing data

09:50-10:10 Design issues of early phase clinical trial in immunotherapy/precision medicine **Byung Ho Nam, PhD**
The Institute of Advanced Clinical & Biomedical Research, Korea

10:10-10:40 Liquid biopsies in early-phase clinical trials **Filip Janku, MD, PhD** MD Anderson Cancer Center, USA

10:40-11:00 **Coffee break**

Session III Immunotherapy versus targeted therapy: promise and pitfalls

11:00-11:30 M7824, bispecific PD-L1 antibody with TGFb-trap, a novel combination of cancer immunotherapy **Motonobu Osada MD, PhD** Merck-Serono Co. Ltd., Japan

11:30-12:00 Avoiding dogma: rationale for combining immunotherapy with chemotherapy and targeted agents vs. other immunomodulators **Brian Lamon, PhD** Bristol-Myers-Squibb Co., USA

12:00-13:10 **Lunch Break**

Session IV Genome-based immunotherapy in precision oncology

13:10-13:30 In vitro generation of memory phenotype antigen-specific cytotoxic T cells **Se Ho Park, PhD** Korea University, Korea

13:30-13:50 Genome based immunotherapy **Jung Kyoon Choi, PhD** KAIST, Korea

13:50-14:20 Biomarker for GI cancer with immunotherapy **Hye Rim Lee, PhD** Merck & Co., Inc., USA

14:20-14:40 **Coffee break**

Session V Emerging novel therapies for cancer

14:40-15:10 Advance in precision oncology with targeted treatment and immunotherapy: Beyond combination **Michael Casarella, Senior Director**
Puma Biotechnology, Inc., USA

15:10-15:40 Next generation ADC envisions paradigm shift of chemotherapy **Koichi Akahane, PhD** Daiichi Sankyo Co., Ltd., Japan

15:40-16:00 Towards next-generation T cell therapy for cancer **Chan Hyuk Kim, PhD** KAIST, Korea

Close